As the name implies, shares of new or small companies are called penny stocks. The price of these shares is usually very low but they also have a lot of potential for growth.
According to experts, there are two companies which have a huge upside potential in 2025. These are Cabaletta Bio (CABA) and Intellia Therapeutics (NTLA). Both of these are biotech companies and are considered a 'Strong Buy', according to experts.
There's a good chance that these 2 penny stocks will gain anywhere from 306% up to 1183% during the next year. Right now, such a bullish forecast appears outright unrealistic but that's not something unheard of!
For example, many AI stocks have gained an astonishing 400 - 600% in 2024 alone. So, who's to say that these biotech stocks can't do the same in 2025.
Intellia Therapeutics (NTLA) is currently valued near $1.4B and is a biotech company at a clinical stage. They are focusing on using the CRISPR/Cas9 technologies for treating genetic diseases. The company have a lot of work in progress and a successful drug could help it to gain massive upside in the stock market.
In 2024, NTLA has lost 51.3% of its value when compared with the SP 500's upside of 26.2%. Despite this, the company remains a strong buy with most of the experts considering it a good penny stock.
The average price target for the NTLA stock is $58.8 which means a 306% upside based on the current levels. Also, some experts are citing a higher target price of $128 for the NTLA.
Cabaletta Bio (CABA) is the second penny stock which has a market cap of around $91.4M. The company is focusing on developing treatments for the autoimmune disease and has an ongoing program called CABA-201.
The Cabaletta Bio (CABA) is also a strong buy based on the opinion of Wall Street experts. The CABA is trading near $1.87 while the experts have set a target of around $24.70. This means the CABA has the potential to gain almost 1183% in 2025.